FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology, in particular to interleukin 10 (IL-10) fusion proteins and a method of treating a malignant tumour. Disclosed is a fused protein of formula (I-VII): IL-10-L1-X1-L1-X2-L1-IL-10 (Formula I); (Z)n-X1-L2-Y2-L1-IL-10 (Formula II); IL-10-L1-Y1-L2-X2-(Z)n (Formula III); X1-L2-X2-L1-IL-10 (Formula IV); IL-10-L1-X1-L2-X2 (Formula V); X1-L1-IL-10 (Formula VI); and IL-10-L1-X2 (Formula VII). "IL-10" is a monomer sequence selected from SEQ ID NO: 1, 3, 14, 15, 16, 18, 19, 55, 57 or 59. "L1" and "L2" are linkers. "X1" and "X2" are the VH and VL regions obtained from the first antibody. "Y1" and "Y2" are the VH and VL regions obtained from the second antibody. "Z" is a cytokine.
EFFECT: inventions provide creation of IL-10 receptor agonists with altered binding affinity to IL-10 receptor and/or altered interdomain angles in IL-10, which can be used for treatment of malignant tumour.
17 cl, 21 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
| IL-10/FC FUSION PROTEINS SUITABLE AS IMMUNOTHERAPY ENHANCERS | 2020 |
|
RU2825306C1 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USE | 2020 |
|
RU2815388C2 |
| CONSTRUCTS FOR DIRECTED GENE EDITING AND METHODS USING THEM | 2020 |
|
RU2832109C2 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| ACTIVATED POLYPEPTIDES OF INTERLEUKIN 12 AND METHODS OF USE THEREOF | 2019 |
|
RU2826183C2 |
| POLYPEPTIDES MODULATING SIGLEC-DEPENDENT IMMUNE RESPONSES | 2017 |
|
RU2776807C2 |
